[
 {
  "trial": "T052",
  "source": "fulltext",
  "arms": {
   "Group E": {
    "randomized": "60",
    "analysed": "58"
   },
   "Group C": {
    "randomized": "60",
    "analysed": "57"
   }
  },
  "depression": [
   {
    "measure": "DSM-IV clinical interview for PPD",
    "day": 7,
    "form": "count",
    "definition": "PPD: EPDS > 9 screen, then DSM-IV clinical interview",
    "location": "Table 2",
    "values": {
     "Group E": {
      "events": "2",
      "n": "58"
     },
     "Group C": {
      "events": "9",
      "n": "57"
     }
    }
   },
   {
    "measure": "DSM-IV clinical interview for PPD",
    "day": 42,
    "form": "count",
    "definition": "PPD: EPDS > 9 screen, then DSM-IV clinical interview",
    "location": "Table 2",
    "values": {
     "Group E": {
      "events": "3",
      "n": "58"
     },
     "Group C": {
      "events": "11",
      "n": "57"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "within 48 h after the operation",
    "location": "Table 2",
    "n": {
     "Group E": "58",
     "Group C": "57"
    },
    "terms": {
     "nightmare": "Nightmares"
    },
    "values": {
     "Group E": {
      "nightmare": "2"
     },
     "Group C": {
      "nightmare": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-04-01",
   "end": "2022-11-30"
  },
  "registration": {
   "number": "ChiCTR2200060387",
   "date": "2022-05-30"
  },
  "note": "Table 2 'PPD' counts use the paper's two-step definition (EPDS > 9 screen, then a DSM-IV clinical interview by physicians blind to group), so they are entered under 'DSM-IV clinical interview for PPD'; the number screening positive on the EPDS is not reported separately, so 'EPDS screen (>9)' has no entry. Results text repeats the percentages (1 week 15.8% vs 3.4%; 6 weeks 19.3% vs 5.2%, C vs E). Randomized 60 per group (Methods 2.3, 'with 60 cases in each group'). Of the Table 2 adverse reactions (within 48 h), only nightmares map to a category (drowsiness is not dizziness). Enrollment dates come from Methods 2.2 and 2.5; the Results don't restate them. Registration (30 May 2022) is after enrollment began (1 April 2022)."
 },
 {
  "trial": "T055",
  "source": "fulltext",
  "arms": {
   "S group": {
    "randomized": "75",
    "analysed": "66"
   },
   "C group": {
    "randomized": "75",
    "analysed": "63"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 3",
    "values": {
     "S group": {
      "mean": "4.12",
      "sd": "0.64",
      "n": "66"
     },
     "C group": {
      "mean": "4.08",
      "sd": "0.63",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 3",
    "values": {
     "S group": {
      "mean": "6.42",
      "sd": "0.75",
      "n": "66"
     },
     "C group": {
      "mean": "6.95",
      "sd": "0.58",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 3",
    "values": {
     "S group": {
      "mean": "8.58",
      "sd": "0.88",
      "n": "66"
     },
     "C group": {
      "mean": "9.05",
      "sd": "0.63",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "mean_sd",
    "location": "Table 3",
    "values": {
     "S group": {
      "mean": "5.86",
      "sd": "0.76",
      "n": "66"
     },
     "C group": {
      "mean": "6.21",
      "sd": "0.68",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression)",
    "values": {
     "S group": {
      "events": "0",
      "n": "66"
     },
     "C group": {
      "events": "0",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression)",
    "values": {
     "S group": {
      "events": "8",
      "n": "66"
     },
     "C group": {
      "events": "8",
      "n": "65"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3 (Occurrence of postpartum depression)",
    "values": {
     "S group": {
      "events": "0",
      "n": "66"
     },
     "C group": {
      "events": "0",
      "n": "65"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (T2, 24 h)",
    "values": {
     "S group": {
      "mean": "3.50",
      "sd": "0.50",
      "n": "66"
     },
     "C group": {
      "mean": "4.17",
      "sd": "0.38",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (T3, 48 h)",
    "values": {
     "S group": {
      "mean": "2.00",
      "sd": "0.00",
      "n": "66"
     },
     "C group": {
      "mean": "2.06",
      "sd": "0.25",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS on movement",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (T2, 24 h)",
    "values": {
     "S group": {
      "mean": "4.50",
      "sd": "0.54",
      "n": "66"
     },
     "C group": {
      "mean": "5.17",
      "sd": "0.38",
      "n": "65"
     }
    }
   },
   {
    "measure": "VAS on movement",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (T3, 48 h)",
    "values": {
     "S group": {
      "mean": "3.00",
      "sd": "0.00",
      "n": "66"
     },
     "C group": {
      "mean": "3.06",
      "sd": "0.25",
      "n": "65"
     }
    }
   },
   {
    "measure": "effective PCIA presses at 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (Total number of PCIA compressions in 48 hours)",
    "values": {
     "S group": {
      "mean": "7.58",
      "sd": "1.50",
      "n": "66"
     },
     "C group": {
      "mean": "14.75",
      "sd": "1.78",
      "n": "65"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "time": "5 min after drug administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Nystagmus",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "65",
      "dizziness": "63",
      "hallucination": "25"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "5 min after drug administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Diplopia"
    },
    "values": {
     "S group": {
      "visual": "7"
     },
     "C group": {
      "visual": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "15 min after drug administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Nystagmus",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "4",
      "dizziness": "6",
      "hallucination": "8"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "15 min after drug administration",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Diplopia"
    },
    "values": {
     "S group": {
      "visual": "1"
     },
     "C group": {
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "on leaving the operating room",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Nystagmus",
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations"
    },
    "values": {
     "S group": {
      "visual": "0",
      "dizziness": "1",
      "hallucination": "0"
     },
     "C group": {
      "visual": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "on leaving the operating room",
    "location": "Table 2",
    "n": {
     "S group": "66",
     "C group": "63"
    },
    "terms": {
     "visual": "Diplopia"
    },
    "values": {
     "S group": {
      "visual": "1"
     },
     "C group": {
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-02-16",
   "end": "2024-04-30"
  },
  "registration": {
   "number": "ChiCTR2400080884",
   "date": "2024-02-15"
  },
  "note": "C group n: Table 3's header prints n = 65, but the flow (75 randomized, 4 excluded for bleeding, 8 lost), Table 1 (N = 63), Table 2 (n = 63) and the 129 analysed in total give 63, and 8 (12.7%) at day 7 fits 63; outcome entries copy Table 3's printed n (66 vs 65), and 'analysed' uses 63. Count entries are Table 3's 'Occurrence of postpartum depression' rows; Methods define PPD as EPDS ≥ 10. Pain T1 (4 h) is out of window. 'Postoperative adjuvant analgesia' (S 2 (3.00%), C 19 (30.2%)) is not a listed measure and has no time point, so it is left out. Adverse events (Table 2) are timed from the study drug, given within 10 min of cord clamping during surgery: 5 and 15 min coded intraoperative, 'Out of operating room' coded postoperative. Nystagmus and diplopia both map to 'visual', so each is its own entry (see 'terms'). S group dizziness and diplopia on leaving the operating room print as '1 (0%)' (count and percent disagree); the count is copied. The text also names blurred vision at 5 min without a number. Enrollment dates are from Methods 2.2 ('conducted from February 16, 2024, to April 30, 2024')."
 },
 {
  "trial": "T077",
  "source": "fulltext",
  "arms": {
   "Esketamine (ESK) group": {
    "randomized": null,
    "analysed": "58"
   },
   "Control (CON) group": {
    "randomized": null,
    "analysed": "58"
   }
  },
  "depression": [
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative SDS score)",
    "values": {
     "Esketamine (ESK) group": {
      "median": "21",
      "q1": "21",
      "q3": "25",
      "n": "58"
     },
     "Control (CON) group": {
      "median": "22",
      "q1": "21",
      "q3": "25",
      "n": "58"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (SDS 24 hours)",
    "values": {
     "Esketamine (ESK) group": {
      "median": "21",
      "q1": "20",
      "q3": "23",
      "n": "58"
     },
     "Control (CON) group": {
      "median": "22",
      "q1": "21",
      "q3": "24",
      "n": "58"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2 (SDS 72 hours)",
    "values": {
     "Esketamine (ESK) group": {
      "median": "20",
      "q1": "20",
      "q3": "21",
      "n": "58"
     },
     "Control (CON) group": {
      "median": "20",
      "q1": "20",
      "q3": "21",
      "n": "58"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS pain score (24, 72 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (VAS 24 hours)",
    "values": {
     "Esketamine (ESK) group": {
      "median": "1",
      "q1": "1",
      "q3": "3",
      "n": "58"
     },
     "Control (CON) group": {
      "median": "2",
      "q1": "1",
      "q3": "4",
      "n": "58"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-11",
   "end": "2025-04"
  },
  "registration": {
   "number": "ChiCTR2400092257",
   "date": null
  },
  "note": "Per-arm randomized numbers are not printed: the Results give 145 randomized in total, then exclusions of 14 in ESK (6 electrode detachment, 4 lost to follow-up, 4 benign histology) and 15 in CON (9, 3, 3), leaving 58 per group in the per-protocol analysis. The Methods' sample-size paragraph instead says 116 were enrolled with 58 allocated to each group. All 145 were in the safety analysis, but adverse-event counts (vomiting, agitation, others) are only in Supplementary Table 1, not in this text. VAS at 72 h (ESK 1 (1, 1), CON 1 (1, 2.5)) is outside the day-2 window and left out. Values are median (IQR) per the Table 1 and 2 notes. Enrollment months are from the Results ('Between November 2024 and April 2025')."
 },
 {
  "trial": "T082",
  "source": "fulltext",
  "arms": {
   "Control (Group C)": {
    "randomized": "40",
    "analysed": "35"
   },
   "Esketamine (Group E)": {
    "randomized": "40",
    "analysed": "35"
   }
  },
  "depression": [
   {
    "measure": "HADS (depression)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 1 (HADS-D score)",
    "values": {
     "Control (Group C)": {
      "median": "4",
      "q1": "1",
      "q3": "6",
      "n": "35"
     },
     "Esketamine (Group E)": {
      "median": "2",
      "q1": "2",
      "q3": "5",
      "n": "35"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2025-02",
   "end": "2025-04"
  },
  "registration": {
   "number": "ChiCTR2500096770",
   "date": "2025-02-06"
  },
  "note": "Group ED (esketamine-dexmedetomidine, role other) is not extracted. Randomized 40 per group ('equally allocated to the three groups (n=40 per group)'); analysed 35 per group from Table 1's header (exclusions C 2 + 3, E 4 + 1). Table 1 doesn't label its summary statistic; Methods say non-normal variables are median (IQR), so HADS-D (POD 2) is coded median_iqr. Baseline HADS is only in Supplementary Table S1. NRS at rest and on movement appear only as Figure 3 boxplots with no printed values, so there are no pain entries. PCIA presses in Table 1 have no stated time window, so they are not coded to day 1 or 2: total compressions C 8(6–8), E 7(4–8); effective compressions C 7(5–7), E 6(4–7). Rescue diclofenac and adverse events are only in supplementary tables (S3, S4). Registration (6 February 2025) falls within the enrollment months (Results: 'Between February and April 2025')."
 },
 {
  "trial": "T083",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": null,
    "analysed": "40"
   },
   "Normal saline group": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Hamilton Depression Rating Scale, POD-1 = day before surgery)",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "7.8",
      "n": "40"
     },
     "Normal saline group": {
      "median": "4.5",
      "q1": "3.0",
      "q3": "7.0",
      "n": "40"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "7.0",
      "n": "40"
     },
     "Normal saline group": {
      "median": "5.5",
      "q1": "5.0",
      "q3": "7.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "2.3",
      "q3": "6.0",
      "n": "40"
     },
     "Normal saline group": {
      "median": "5.1",
      "q1": "4.1",
      "q3": "7.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "3.00",
      "q1": "2.1",
      "q3": "4.1",
      "n": "40"
     },
     "Normal saline group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "6.2",
      "n": "40"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Self-Rating Depression Scale, POD-1 = day before surgery)",
    "values": {
     "Esketamine group": {
      "median": "39.5",
      "q1": "32.9",
      "q3": "43.1",
      "n": "40"
     },
     "Normal saline group": {
      "median": "35.5",
      "q1": "31.1",
      "q3": "44.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "36.8",
      "q1": "34.5",
      "q3": "39.0",
      "n": "40"
     },
     "Normal saline group": {
      "median": "40.9",
      "q1": "38.1",
      "q3": "43.7",
      "n": "40"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "33.8",
      "q1": "31.9",
      "q3": "35.8",
      "n": "40"
     },
     "Normal saline group": {
      "median": "40.3",
      "q1": "37.8",
      "q3": "42.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "33.0",
      "q1": "31.0",
      "q3": "34.9",
      "n": "40"
     },
     "Normal saline group": {
      "median": "42.2",
      "q1": "37.3",
      "q3": "43.1",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "11-point VAS (30 min after extubation, POD1, POD2)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4 (T4, 1 day after surgery)",
    "values": {
     "Esketamine group": {
      "median": "3.00",
      "q1": "3.00",
      "q3": "4.00",
      "n": "40"
     },
     "Normal saline group": {
      "median": "3.00",
      "q1": "2.00",
      "q3": "4.00",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "time": "during infusion through 72 h postoperatively",
    "location": "Table 5",
    "n": {
     "Esketamine group": "40",
     "Normal saline group": "40"
    },
    "terms": {
     "dizziness": "Dizziness",
     "visual": "Diplopia",
     "hallucination": "Hallucination or daymare",
     "nightmare": "Hallucination or daymare",
     "agitation": "Agitation (RASS ≥ 2 during drug infusion)",
     "psychiatric_any": "Neuropsychiatric symptoms"
    },
    "values": {
     "Esketamine group": {
      "dizziness": "4",
      "visual": "0",
      "hallucination": "0",
      "nightmare": "0",
      "agitation": "0",
      "psychiatric_any": "4"
     },
     "Normal saline group": {
      "dizziness": "0",
      "visual": "0",
      "hallucination": "0",
      "nightmare": "0",
      "agitation": "0",
      "psychiatric_any": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-10",
   "end": "2024-04"
  },
  "registration": {
   "number": "ChiCTR2200061575",
   "date": "2022-06-29"
  },
  "note": "Per-arm randomized numbers are not printed: 90 randomized in total, then 5 per group excluded (loss to follow-up or withdrawal), 40 per group analysed. Table 1's baseline rows run together in the text ('IIIHamilton Depression Rating Scale ... POD-1Self-Rating Depression Scale'); read as HAMD-17 POD-1 NS 4.5 (3.0, 7.0) vs ESK 5.0 (4.0, 7.8), SDS POD-1 NS 35.5 (31.1, 44.1) vs ESK 39.5 (32.9, 43.1), where POD-1 is the day before surgery. HAMD-17 day 30: the Results text prints 3.00 (2.08–4.10) vs 5.00 (4.00–6.20); Table 2's 3.00 (2.1–4.1) vs 5.0 (4.0–6.2) is used. Table 2 labels all values median (IQR), though the SDS intervals are nearly symmetric about the centre. Pain T5: Methods call it postoperative day 2, but Table 4's notes and the Results text say 3 days after surgery, so it is left out (2.00 (2.00–3.00) in both groups); T3 (30 min after extubation) is day 0. AE window coded overall, since Table 5 mixes events during infusion with the 72 h postoperative monitoring. 'Hallucination or daymare' (0 vs 0) is coded 0 for hallucination and nightmare (Methods name hallucinations and nightmares as the psychotomimetic effects monitored). 'Neuropsychiatric symptoms' (ESK 4, NS 0) is coded psychiatric_any; it sits beside zero counts for hallucination, agitation and diplopia. Enrollment months are from Methods ('from October 2023 and April 2024')."
 },
 {
  "trial": "T103",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "105",
    "analysed": "98"
   },
   "Placebo group": {
    "randomized": "105",
    "analysed": "100"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative HADS-D score)",
    "values": {
     "Esketamine group": {
      "median": "7.0",
      "q1": "5.0",
      "q3": "10.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "7.0",
      "q1": "5.0",
      "q3": "9.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "6.0",
      "q1": "4.0",
      "q3": "7.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "8.0",
      "q1": "6.0",
      "q3": "8.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "3.0",
      "q3": "6.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "7.0",
      "q1": "5.0",
      "q3": "8.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "2.0",
      "q3": "5.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "7.0",
      "n": "100"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest (24-h average)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "1.0",
      "q1": "0.0",
      "q3": "2.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "3.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "NRS at rest (24-h average)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "1.0",
      "q1": "0.0",
      "q3": "2.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "3.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "NRS during movement (24-h average)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "5.0",
      "q1": "3.0",
      "q3": "6.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "NRS during movement (24-h average)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "98"
     },
     "Placebo group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "BPI pain severity and interference",
    "subscale": "BPI pain items",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "3.5",
      "n": "98"
     },
     "Placebo group": {
      "median": "3.8",
      "q1": "1.8",
      "q3": "4.0",
      "n": "100"
     }
    }
   },
   {
    "measure": "BPI pain severity and interference",
    "subscale": "BPI pain items",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "1.8",
      "q1": "1.0",
      "q3": "2.8",
      "n": "98"
     },
     "Placebo group": {
      "median": "3.0",
      "q1": "1.8",
      "q3": "3.5",
      "n": "100"
     }
    }
   },
   {
    "measure": "BPI pain severity and interference",
    "subscale": "BPI interference items",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.7",
      "q3": "4.4",
      "n": "98"
     },
     "Placebo group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "5.3",
      "n": "100"
     }
    }
   },
   {
    "measure": "BPI pain severity and interference",
    "subscale": "BPI interference items",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3.3",
      "q1": "3.1",
      "q3": "3.6",
      "n": "98"
     },
     "Placebo group": {
      "median": "4.0",
      "q1": "3.7",
      "q3": "4.4",
      "n": "100"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "within 7 days after surgery",
    "location": "Table 4",
    "n": {
     "Esketamine group": "98",
     "Placebo group": "100"
    },
    "terms": {
     "nightmare": "Nightmares"
    },
    "values": {
     "Esketamine group": {
      "nightmare": "6"
     },
     "Placebo group": {
      "nightmare": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-10",
   "end": "2025-01"
  },
  "registration": {
   "number": "ChiCTR2400088916",
   "date": "2024-08-29"
  },
  "note": "Analysed is the modified ITT set (98 and 100: esketamine 3 conversions to laparotomy and 4 ICU stays over 24 h; placebo 2 and 3); Figure 1's caption gives 97 per-protocol in the esketamine group. Tables 2 and 3 give median (lower quartile, upper quartile); their MD (95% CI) column (median differences) is not extracted because arm values are given. Figure 3's caption describes approximate plotted HADS-D values; not used. The design names one measure 'BPI pain severity and interference', which Table 3 reports as two rows ('BPI pain items', 'BPI interference items'); each is entered under the design's name with 'subscale' naming the row. Pain scores are averages over the past 24 h, assessed on each POD; POD 3 is out of window. Of the Table 4 drug-related complications (within 7 days), only nightmares map to a category. Enrollment months are from Methods 2.2 ('Between October 2024 and January 2025 ... screened')."
 },
 {
  "trial": "T114",
  "source": "fulltext",
  "arms": {
   "ES group": {
    "randomized": null,
    "analysed": "26"
   },
   "Control group": {
    "randomized": null,
    "analysed": "27"
   }
  },
  "depression": [
   {
    "measure": "Zung SDS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (T0, PreOP)",
    "values": {
     "ES group": {
      "mean": "53.76",
      "sd": "4.83",
      "n": "26"
     },
     "Control group": {
      "mean": "53.25",
      "sd": "3.72",
      "n": "27"
     }
    }
   },
   {
    "measure": "Zung SDS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (T1, POD 1)",
    "values": {
     "ES group": {
      "mean": "47.69",
      "sd": "2.98",
      "n": "26"
     },
     "Control group": {
      "mean": "53.85",
      "sd": "3.37",
      "n": "27"
     }
    }
   },
   {
    "measure": "Zung SDS",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 2 (T2, POD 3)",
    "values": {
     "ES group": {
      "mean": "45.61",
      "sd": "2.55",
      "n": "26"
     },
     "Control group": {
      "mean": "54.44",
      "sd": "3.02",
      "n": "27"
     }
    }
   },
   {
    "measure": "Zung SDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2 (T3, POD 7)",
    "values": {
     "ES group": {
      "mean": "43.07",
      "sd": "2.30",
      "n": "26"
     },
     "Control group": {
      "mean": "52.70",
      "sd": "2.77",
      "n": "27"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS pain",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 7",
    "values": {
     "ES group": {
      "mean": "1.46",
      "sd": "0.82",
      "n": "26"
     },
     "Control group": {
      "mean": "2.43",
      "sd": "1.07",
      "n": "27"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-11",
   "end": "2025-08"
  },
  "registration": {
   "number": "ChiCTR2500098063",
   "date": null
  },
  "note": "The source labels the control arm 'C group'. Per-arm randomized numbers are not printed: 58 randomized in total (Methods' enrollment target 29 per group), 5 lost to follow-up before POD 7, 53 in the per-protocol efficacy analysis (C 27, ES 26); all 58 were in the safety analysis. Baseline SDS is taken from Table 2 (T0); Table 1 prints different values (C 53.23 ± 3.66, ES 53.53 ± 4.71, p = 0.7842). Table 2's 95% CI row is for the between-group difference (not extracted; arm values are given). Counts of SDS ≥ 53 are not reported. Table 7's VAS has no time label; Methods say VAS was assessed on POD 1. Table 7 lists only headache, nausea/vomiting and drowsiness (adverse events within 24 h), so no psychotomimetic events are recorded. Enrollment months are from Methods ('From November 2024 to August 2025'); registration date not given."
 },
 {
  "trial": "T124",
  "source": "preprint",
  "arms": {
   "Group T (esketamine)": {
    "randomized": null,
    "analysed": "40"
   },
   "Group C (saline)": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4 (Preoperative Day)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.4",
      "sd": "1.8",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.8",
      "sd": "1.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 4 (1 week post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "5.3",
      "sd": "2.7",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "6.5",
      "sd": "2.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "mean_sd",
    "location": "Table 4 (6 weeks post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "4.3",
      "sd": "2.8",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "5.6",
      "sd": "2.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 13",
    "location": "Table 4 (Incidence of PPD, 1 week post-op)",
    "values": {
     "Group T (esketamine)": {
      "events": "3",
      "n": "40"
     },
     "Group C (saline)": {
      "events": "10",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "definition": "EPDS ≥ 13",
    "location": "Table 4 (Incidence of PPD, 6 weeks post-op)",
    "values": {
     "Group T (esketamine)": {
      "events": "2",
      "n": "40"
     },
     "Group C (saline)": {
      "events": "8",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.5",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.0",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.0",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "2.5",
      "sd": "1.0",
      "n": "40"
     }
    }
   },
   {
    "measure": "dynamic NRS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.6",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "4.2",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "dynamic NRS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.0",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.6",
      "sd": "1.2",
      "n": "40"
     }
    }
   },
   {
    "measure": "uterine contraction pain NRS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (24h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "3.1",
      "sd": "1.1",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.7",
      "sd": "1.2",
      "n": "40"
     }
    }
   },
   {
    "measure": "uterine contraction pain NRS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "2.7",
      "sd": "1.2",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "3.3",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "PCIA bolus requests (tramadol)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Number of rescue analgesia requests, 48h post-op)",
    "values": {
     "Group T (esketamine)": {
      "mean": "1.9",
      "sd": "1.4",
      "n": "40"
     },
     "Group C (saline)": {
      "mean": "2.7",
      "sd": "1.4",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "postoperative observation period",
    "location": "Table 5",
    "n": {
     "Group T (esketamine)": "40",
     "Group C (saline)": "40"
    },
    "terms": {
     "dizziness": "Dizziness",
     "agitation": "Agitation/excitement",
     "any_ae": "Overall incidence of adverse events"
    },
    "values": {
     "Group T (esketamine)": {
      "dizziness": "3",
      "agitation": "1",
      "any_ae": "19"
     },
     "Group C (saline)": {
      "dizziness": "2",
      "agitation": "0",
      "any_ae": "16"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-10",
   "end": "2025-05"
  },
  "registration": {
   "number": "ChiCTR2400090341",
   "date": "2024-09-27"
  },
  "note": "Per-arm randomized numbers are not printed in the Results: 84 randomized in total, 2 per group converted to general anesthesia and excluded, none lost, 40 per group analysed; the abstract instead says 80 were randomized, 40 per group; Methods planned 44 per group (88 enrolled, 4 refused). Count entries are Table 4's 'Incidence of PPD' (positive screen, EPDS ≥ 13 per Methods); 1 and 6 weeks post-op coded days 7 and 42. Pain at 2, 6 and 12 h is out of window. The design's 'PCIA bolus requests (tramadol)' is Table 2's row 'Number of rescue analgesia requests' at 48 h (the Results text calls it the number of PCIA bolus requests within 48 hours; Methods say it was recorded at 24 and 48 h, but only 48 h is printed). Somnolence (T 2, C 1) maps to no category. The abstract says blurred vision and irritability were slightly higher in Group T without numbers; the Discussion says no hallucinations were recorded (no printed count, not coded). Registration: the abstract and Declarations say retrospectively registered (27/09/2024); Methods say registered before enrollment. Enrollment months are from Methods ('from October 2024 to May 2025')."
 },
 {
  "trial": "T125",
  "source": "preprint",
  "arms": {
   "Esketamine group": {
    "randomized": "62",
    "analysed": "60"
   },
   "Control group": {
    "randomized": "62",
    "analysed": "61"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 3 (Preoperative)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "2.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (24 h)",
    "values": {
     "Esketamine group": {
      "median": "8.0",
      "q1": "6.0",
      "q3": "9.0",
      "n": "60"
     },
     "Control group": {
      "median": "9.0",
      "q1": "8.0",
      "q3": "10.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3 (72 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "6.0",
      "n": "61"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (Resting VAS, 24 h)",
    "values": {
     "Esketamine group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": "60"
     },
     "Control group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "VAS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (Resting VAS, 48 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "60"
     },
     "Control group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "3.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "movement-evoked VAS",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (24 h)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "movement-evoked VAS",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (48 h)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "60"
     },
     "Control group": {
      "median": "5.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "effective PCA presses",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2 (24 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "60"
     },
     "Control group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "effective PCA presses",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 (48 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "60"
     },
     "Control group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "rescue butorphanol within 24 h",
    "day": 1,
    "form": "count",
    "definition": "rescue IV butorphanol (given for VAS > 5) within 24 h",
    "location": "Table 2 (24-h rescue analgesia, n (%))",
    "values": {
     "Esketamine group": {
      "events": "6",
      "n": "60"
     },
     "Control group": {
      "events": "15",
      "n": "61"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "time": "not stated",
    "location": "Table 5",
    "n": {
     "Esketamine group": "60",
     "Control group": "61"
    },
    "terms": {
     "dizziness": "Dizziness",
     "hallucination": "Hallucinations / nightmares",
     "nightmare": "Hallucinations / nightmares",
     "any_ae": "Total"
    },
    "values": {
     "Esketamine group": {
      "dizziness": "1",
      "hallucination": "0",
      "nightmare": "0",
      "any_ae": "4"
     },
     "Control group": {
      "dizziness": "2",
      "hallucination": "0",
      "nightmare": "0",
      "any_ae": "6"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2025-04",
   "end": "2025-12"
  },
  "registration": {
   "number": "ChiCTR2500099435",
   "date": null
  },
  "note": "Randomized 62 per group; 3 withdrawn after randomization (control 1 conversion to general anesthesia; esketamine 1 hemorrhage, 1 intrauterine balloon), analysed 60 vs 61. EPDS at 24 h and 72 h coded days 1 and 3; follow-up ended at 72 h. Values are median (P25, P75); the Hodges-Lehmann differences are not extracted. Pain at 2 h and 6 h and PCA presses at 6 h and 12 h are out of window. 'Hallucinations / nightmares' is one row (0 vs 0) and the text says neither group experienced hallucinations or nightmares, so both are coded 0. The adverse-event window isn't stated (coded overall). Enrollment months are from the Results ('Between April and December 2025'); the last participant was assessed on December 2, 2025. Registration is stated as retrospective, with no date."
 }
]